Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delavirdine Mesylate

This publication has 16 references indexed in Scilit:

• Solid Phases of Delavirdine Mesylate
  Journal of Pharmaceutical Sciences, 1996
• Global burden of the HIV pandemic
  The Lancet, 1996
• Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients
  Antimicrobial Agents and Chemotherapy, 1995
• Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
  Nature, 1995
• Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro
  Antimicrobial Agents and Chemotherapy, 1994
• HIV resistance to reverse transcriptase inhibitors
  Biochemical Pharmacology, 1994
• A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
  Proceedings of the National Academy of Sciences, 1993
• U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication
  Antimicrobial Agents and Chemotherapy, 1993
• The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
  New England Journal of Medicine, 1987
• Pneumocystis cariniiPneumonia and Mucosal Candidiasis in Previously Healthy Homosexual Men
  New England Journal of Medicine, 1981